HALOZYME THERAPEUTICS INC (HALO) Fundamental Analysis & Valuation

NASDAQ:HALO • US40637H1095

Current stock price

63.66 USD
+0.6 (+0.95%)
At close:
64.294 USD
+0.63 (+1%)
After Hours:

This HALO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. HALO Profitability Analysis

1.1 Basic Checks

  • In the past year HALO was profitable.
  • HALO had a positive operating cash flow in the past year.
  • In the past 5 years HALO has always been profitable.
  • HALO had a positive operating cash flow in each of the past 5 years.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • The Return On Assets of HALO (12.55%) is better than 93.98% of its industry peers.
  • HALO has a better Return On Equity (649.18%) than 100.00% of its industry peers.
  • With an excellent Return On Invested Capital value of 25.65%, HALO belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
  • HALO had an Average Return On Invested Capital over the past 3 years of 20.76%. This is significantly below the industry average of 28.06%.
  • The last Return On Invested Capital (25.65%) for HALO is above the 3 year average (20.76%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • The Profit Margin of HALO (22.69%) is better than 93.20% of its industry peers.
  • In the last couple of years the Profit Margin of HALO has declined.
  • HALO has a Operating Margin of 58.45%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 83.62%, HALO belongs to the best of the industry, outperforming 86.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of HALO has remained more or less at the same level.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HALO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
  • HALO has less shares outstanding than it did 1 year ago.
  • HALO has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, HALO has a worse debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 3.77 indicates that HALO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.77, HALO is in the better half of the industry, outperforming 71.65% of the companies in the same industry.
  • HALO has a debt to FCF ratio of 6.00. This is a slightly negative value and a sign of low solvency as HALO would need 6.00 years to pay back of all of its debts.
  • HALO's Debt to FCF ratio of 6.00 is amongst the best of the industry. HALO outperforms 90.87% of its industry peers.
  • A Debt/Equity ratio of 43.89 is on the high side and indicates that HALO has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 43.89, HALO is doing worse than 84.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.77
ROIC/WACC3.02
WACC8.48%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • HALO has a Current Ratio of 4.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO's Current ratio of 4.66 is in line compared to the rest of the industry. HALO outperforms 51.84% of its industry peers.
  • HALO has a Quick Ratio of 3.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO has a Quick ratio (3.66) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HALO Growth Analysis

3.1 Past

  • HALO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.36%.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 35.63% on average per year.
  • Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 37.55%.
  • HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.16% yearly.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.17% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.08% on average over the next years.
EPS Next Y97.97%
EPS Next 2Y55.93%
EPS Next 3Y36.6%
EPS Next 5Y16.17%
Revenue Next Year26.75%
Revenue Next 2Y19.45%
Revenue Next 3Y15.71%
Revenue Next 5Y5.08%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. HALO Valuation Analysis

4.1 Price/Earnings Ratio

  • HALO is valuated correctly with a Price/Earnings ratio of 15.41.
  • Based on the Price/Earnings ratio, HALO is valued cheaper than 95.34% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.77. HALO is valued slightly cheaper when compared to this.
  • HALO is valuated cheaply with a Price/Forward Earnings ratio of 7.79.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.45% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.75. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 15.41
Fwd PE 7.79
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 95.92% of the companies are valued more expensively.
  • 94.95% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.14
EV/EBITDA 10.46
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HALO may justify a higher PE ratio.
  • HALO's earnings are expected to grow with 36.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)0.43
EPS Next 2Y55.93%
EPS Next 3Y36.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HALO Dividend Analysis

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALO Fundamentals: All Metrics, Ratios and Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/30/2026, 8:00:02 PM)

After market: 64.294 +0.63 (+1%)

63.66

+0.6 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)02-17
Earnings (Next)05-12
Inst Owners107.43%
Inst Owner Change-0.04%
Ins Owners0.86%
Ins Owner Change0.92%
Market Cap7.54B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.59 (36.02%)
Short Float %12.17%
Short Ratio8.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)0.46%
PT rev (3m)10.07%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)-13.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.15%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.83%
Valuation
Industry RankSector Rank
PE 15.41
Fwd PE 7.79
P/S 5.4
P/FCF 21.14
P/OCF 11.58
P/B 154.5
P/tB N/A
EV/EBITDA 10.46
EPS(TTM)4.13
EY6.49%
EPS(NY)8.18
Fwd EY12.84%
FCF(TTM)3.01
FCFY4.73%
OCF(TTM)5.5
OCFY8.64%
SpS11.79
BVpS0.41
TBVpS-12.77
PEG (NY)0.16
PEG (5Y)0.43
Graham Number6.18777 (-90.28%)
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.77
F-Score5
WACC8.48%
ROIC/WACC3.02
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y97.97%
EPS Next 2Y55.93%
EPS Next 3Y36.6%
EPS Next 5Y16.17%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.75%
Revenue Next 2Y19.45%
Revenue Next 3Y15.71%
Revenue Next 5Y5.08%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year38.07%
EBIT Next 3Y22.25%
EBIT Next 5Y8.86%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


What is the profitability of HALO stock?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 15.41 and the Price/Book (PB) ratio is 154.5.


What is the expected EPS growth for HALOZYME THERAPEUTICS INC (HALO) stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 97.97% in the next year.